Acacia research corp (ACTG)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11
Cash flows from operating activities:
Net loss including noncontrolling interests in subsidiaries

-11,291

-

-

-

-4,398

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss including noncontrolling interests in subsidiaries

-

-

-

-

-

-

-32,864

-28,506

-32,111

-110,300

158,369

-14,264

-12,121

-10,877

6,896

-40,921

-9,897

-117,350

-27,353

777

-13,552

-16,141

-12,835

-13,116

-24,570

-34,989

-15,486

-13,480

5,113

9,722

-6,467

6,381

49,653

-4,296

10,546

1,839

13,556

Adjustments to reconcile net loss including noncontrolling interests in subsidiaries to net cash provided by (used in) operating activities:
Gain on investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9

Change in fair value of investment, net (Note 5)

4,108

277

-4,266

6,980

6,908

-5,142

-24,211

11,347

-41,097

-

158,979

-12,698

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on sale of investment (Note 5)

3,316

-

-

-

5,590

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

1,064

883

862

822

660

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of Series A redeemable convertible preferred stock embedded derivative

-3,708

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of Series A warrants

958

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of Series B warrants

-1,631

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

-

-

5,344

5,463

5,646

5,594

5,540

6,250

6,501

10,801

10,803

13,160

13,743

13,285

13,101

10,296

13,587

15,614

14,552

12,190

12,680

12,631

11,774

18,134

10,449

5,427

5,158

1,457

1,975

2,624

3,794

Non-cash stock compensation

332

322

300

461

-8

-489

-10

1,206

-1,024

-4,183

9,453

1,487

2,128

3,308

2,544

1,475

1,735

2,460

2,164

3,177

3,247

4,093

3,954

5,303

4,765

7,082

9,386

6,268

5,158

8,282

6,285

6,000

5,090

3,688

3,568

3,422

2,901

Change in value of trading securities

-6,005

1,327

-90

-73

1,077

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Increase (Decrease) in Debt Securities, Trading

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of trading securities

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from (Payments for) Trading Securities, Short-term

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-137

-438

2,106

-

18,491

10,552

0

-

-1,024

-10,815

5,293

0

0

0

0

Other

-

-

-

-

-

70

-193

-226

-87

99

125

-250

-348

-396

-99

-51

69

18

0

-115

-12

-4

-24

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Changes in assets and liabilities:
Increase (Decrease) in Restricted Cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,103

5

2,513

798

-21,446

3

0

10,718

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts receivable

110

-1,288

-13,509

-8,656

-8,920

22,312

4,943

875

59

53,047

-13,945

6,464

-18,969

-13,450

49,375

-20,850

-8,325

-5,921

-24,793

7,543

9,839

-20,188

-12,483

11,645

7,199

-3,467

31

-28,570

35,508

-20,648

5,813

9,542

-1,635

-19,501

12,194

19,168

-6,789

Prepaid expenses and other assets

784

-763

-612

1,054

541

25

-388

-292

863

-1,009

-600

-264

1,738

2,784

-537

-788

134

-1,188

-222

89

702

4,873

5

-1,786

62

-11,166

3

4,202

1,661

-2,779

1,214

-648

919

2,024

-1,012

-274

337

Accounts payable and accrued expenses

-908

-217

-1,280

-737

2,343

-89

191

-204

1,065

259

-1,554

-2,478

-2,576

-8,398

11,272

-3,147

-2,733

-110

5,972

-1,159

-2,133

-1,785

-233

4,996

740

-4,134

-488

-1,068

8,430

-7,989

-3,551

3,492

10,303

-44

-240

-1,279

782

Royalties and contingent legal fees payable

-108

-96

-8,244

-5,631

-6,539

15,495

2,428

-35,172

36,608

-18,223

10,397

6,349

-10,830

-11,101

7,155

-764

3,740

5,635

-10,938

1,052

4,778

-3,426

-2,535

16,417

-6,552

2,134

-11,673

-16,750

24,228

-8,970

2,375

5,008

-9,413

-13,542

14,359

955

8,976

Net cash used in operating activities

-2,211

63,440

278

-64,068

-1,958

13,378

-2,132

-40,339

49,970

-21,957

40,250

-4,351

-976

10,842

-14,574

26,683

11,110

-12,104

8,600

9,385

-15,830

-9,706

14,529

19,793

-20,432

1,310

-22,923

1,279

16,825

34,373

6,825

14,453

48,952

16,451

19,020

-11,333

36,452

Cash flows from investing activities:
Patent acquisition costs

5,780

0

0

4,420

0

-

-

-

-

-

-

-

-

225

0

0

1,000

0

837

1,806

16,861

18,228

2,422

21,109

987

14,645

4,156

2,250

4,010

113,300

24,525

38,335

2,100

11,875

1,000

1,125

680

Sale of investment at fair value (Note 5)

905

368

1,215

1,751

3,294

8,657

10,440

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of trading securities

29,501

-

-

-

60,193

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments to Acquire Businesses, Net of Cash Acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

150,000

0

0

0

0

Payments to Acquire Other Investments

-

-

-

-

-

-

-

-

7,000

0

0

31,514

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of available-for-sale investments

-

-

-

-

-

-

15,988

16,586

33,309

23,443

93,533

157,260

174,152

0

12,956

49,677

0

0

0

9,927

13,369

33,833

42,771

19,125

14,234

46,884

57,767

77,817

97,225

97,493

65,055

95,190

144,762

0

8,427

0

0

Maturities and sales of trading securities

35,046

75,090

0

-3,339

3,339

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Maturities and sale of available-for-sale investments

-

-

-

-

-

-

-

-

4,000

80,870

91,113

193,125

102,682

10,880

14,890

17,462

0

0

37,270

26,266

18,579

48,237

45,137

40,109

48,632

83,701

61,860

40,547

53,262

153,220

51,554

97,462

20,000

0

25

0

35

Purchases of property and equipment

163

-

-

-

6

-

-

-

0

-

-

-

-

0

0

0

4

0

0

8

0

3

9

1

96

96

214

124

241

68

12

164

24

18

84

29

59

Net cash provided by (used in) investing activities

507

-71,784

3,096

54,191

-53,566

5,869

11,560

-5,186

-36,309

57,425

-2,420

1,351

-72,470

655

-8,066

-32,215

-1,004

0

36,433

14,525

-11,651

-3,827

-65

-126

33,315

22,076

-277

-39,644

-48,214

-57,641

-38,038

-36,227

-276,886

-11,893

-9,486

-1,154

-704

Cash flows from financing activities:
Repurchase of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-22

0

-101

219,084

-3

0

-52

175,284

Repurchase of common stock

1,314

0

0

0

0

0

0

4,627

7

-35

0

10

25

57

0

25

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Dividend on Series A Redeemable Convertible Preferred Stock

263

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

6,343

6,342

6,374

6,375

6,266

6,260

6,258

6,255

6,241

6,243

6,149

0

-

-

-

-

-

-

-

-

Issuance of Series B warrants

4,600

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Distributions to noncontrolling interests in operating subsidiary

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

2,017

880

Proceeds from exercise of stock options

-

-

-

-

-

0

206

20

31

65

31

394

255

84

242

0

0

0

0

0

938

8

13

95

90

185

60

124

117

66

186

4

84

0

7

360

44

Contributions from noncontrolling interests in operating subsidiary, net of issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

1,920

1,953

1,920

0

1,920

662

0

0

877

Excess tax benefits from stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,040

-1,205

138

709

5,656

-3,296

3,239

7,611

-1,147

1,707

0

23

Net cash provided by financing activities

3,023

33,842

0

79

0

0

-16

-4,614

24

55

31

384

230

27

-1,116

-25

0

-10,448

-6,342

-6,374

-5,437

-6,258

-6,247

-7,030

-6,165

-15,004

-7,406

-5,887

2,746

-19,079

-1,502

3,142

228,699

-488

1,714

-1,709

175,348

Increase (decrease) in cash and cash equivalents and restricted cash

1,319

-

-

-

-55,524

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Decrease in cash and cash equivalents

-

-

-

-

-

-

9,412

-50,139

13,685

35,523

37,861

-2,616

-73,216

11,524

-23,756

-5,557

10,106

-22,552

38,691

17,536

-32,918

-19,791

8,217

12,637

6,718

8,382

-30,606

-44,252

-28,643

-42,347

-32,715

-18,632

765

4,070

11,248

-14,196

211,096

Excess tax benefits from stock-based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,756

-1,205

138

709

-20,764

-3,296

3,239

7,611

-

-

-

-

Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-348

0

0

10,237

0

0

0

0

Payments to Acquire Notes Receivable

-

-

-

-

-

-

-

-

-

0

0

3,000

1,000

10,000

10,000

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Patent acquisition costs included in accrued expenses

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

900

14,700

-1,000

-12,250

15,250

-5,750

1,242

8,508

0

-

-

-

-

-

-

-

-